New York, September 10, 2015 -- Moody's Investors Service commented that the acquisition of Seahorse Bioscience (unrated) by Agilent Technologies Inc. (Agilent) for $235 million is credit negative. However, there is no effect on Agilent's current Baa2 senior unsecured debt rating. The rating outlook is stable.

Vollständigen Artikel bei Moodys lesen